Comparison · NCT00090259-9db870da
Losartan 50 mg vs Losartan 150 mg: Number of Participants That Experienced Cardiovascular Hospitalization
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Losartan 50 mg vs Losartan 150 mg: Number of Participants That Experienced Cardiovascular Hospitalization. Trial comparisons, record NCT00090259-9db870da. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00090259-9db870da
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.432 | 0.41 | 0.454 | wilson | |
| Risk in group 2 | 0.397 | 0.375 | 0.419 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0351 | 0.00393 | 0.0662 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.09 | 1.01 | 1.17 | log | |
| Odds ratio, group 1 over group 2 | 1.16 | 1.02 | 1.31 | log | |
| Number needed to treat, for one more participant with the outcome on Losartan 50 mg than on Losartan 150 mg | 28.5 | 15.1 | 254 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Losartan 50 mg | 826 | 1,913 | OG000 | |
| Group 2 | Losartan 150 mg | 762 | 1,921 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants That Experienced Cardiovascular Hospitalization
- Description
- Time frame
- Entire follow-up (median = 4.7 years)
- Population
- Intention-to-Treat
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)
- NCT number
- NCT00090259
- Phases
- PHASE3
- Conditions
- Heart Failure
- Interventions
- Losartan 50 mg, Losartan 150 mg
- Lead sponsor
- Organon and Co
- Results first posted
- 2010-08-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00090259?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00090259-9db870da